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Abstract
This study examines the effect of the antidepressants fluoxetine, sertraline and amitriptyline on cholinesterase (acetylcholinesterase
(AChE) and butyrylcholinesterase (BuChE)) activities in human serum and erythrocyte membrane (ghost). The concentrations used range
from 3 to 60 AM for fluoxetine and amitriptyline and 0.3 to 12 AM for sertraline. At the micromolar range concentration, different classes of
antidepressants, including fluoxetine and sertraline (selective serotonin reuptake inhibitors (SSRIs)) and amitriptyline (tricyclic
antidepressant) inhibited human serum cholinesterase. The order of inhibitory potency was sertraline>amitriptylineHfluoxetine and the
IC50 values were 4.05, 9.43 and 62 AM, respectively. Analysis of kinetic data indicated that the inhibition caused by all the antidepressants
was mixed in nature. At the micromolar range concentration, sertraline (60–120 AM) and amitriptyline (60–180 AM) inhibited human
erythrocyte AChE. The order of inhibitory potency was sertraline>amitriptyline and the IC50 values were 80 and 134 AM, respectively.
Analysis of kinetic data indicated that the inhibition caused by all the antidepressants in AChE human erythrocyte membrane (ghost) was
mixed in nature. The interaction of sertraline with the cholinesterase is labile since the removal of inhibitor by gel filtration recovered
completely the enzyme activity. Our results demonstrate that the usual clinical antidepressants are inhibitors of the cholinesterases on human
serum and erythrocyte membrane. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Mammals have two main classes of cholinesterases:
acetylcholinesterase (AChE, E.C. 3.1.1.7) and butyrylcho-
linesterase (BuChE, E.C. 3.1.1.8). These distinct enzymes
possess differences in their tissue distribution, kinetic prop-
erties, specificity for synthetic and natural substrates and
selective inhibitors [1–4] although they are evolutionarily
related. For instance, the influence of substrate concentra-
tion on enzyme activity is quite different depending on the
considered cholinesterase. In fact, AChE is inhibited, while
BuChE is activated by an increase in substrate concentra-
tion. In humans, AChE is more abundant in the central
nervous system, end plate of skeletal muscle and erythro-
cytes membranes while BuChE is more abundant in serum
[5].
BuChE, also called nonspecific cholinesterase or pseu-
docholinesterase, is able to act on hydrophilic and hydro-
phobic choline esters [6]. At this moment, the exact
physiological function of BuChE is not yet clear, but it is
well known that this enzyme hydrolyses a variety of xeno-
biotics such as aspirin, succinylcholine, heroin and cocaine
[7]. Recently, it was suggested that BuChE was found co-
localised with senile plaques in the central nervous system,
and plays a role in the progressive h-amyloid aggregation
and in senile plaques maturation [8].
AChE is an important regulatory enzyme that controls
the transmission of nerve impulses across cholinergic syn-
apses by hydrolysing the excitatory transmitter acetylcho-
line (ACh) [9,10]. Of toxicological and pharmacological
significance, AChE is a target for various cholinergic toxins,
such as natural snake venom and plant glycoalkaloids, and
also a target for therapeutically active compounds, including
anti-Alzheimer’s disease drugs. However, there is growing
evidence that cholinesterase, probably through their ‘non-
cholinergic’ functions, could participate in the pathological
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processes in Alzheimer’s disease such as the h-amyloid
formation or deposition [11]. In this way, ChE inhibitors
may modulate the processing of h-amyloid protein, thus
reducing the deposition of h-amyloid itself [12].
The enzyme reaction catalysed by acetylcholinesterase is
one of the most efficient reactions known. This efficiency
could be due to the three-dimensional structure of the
enzyme. The long and narrow active site gorge is about
20 A˚ deep and includes two sites of ligand interaction: an
acylation site at the base of the gorge with the catalytic triad
and a peripheral site at its mouth [13]. Some ligands can
bind specifically to the acylation or to the peripheral site,
and ternary complexes with different ligands bound to each
site can be formed.
In BuChE and AChE, the hydrolysis is carried out by a
‘‘catalytic triad’’ of Ser, His and Glu in the active center
[14]. Therefore, there are some differences in the catalytic
course; for example, BuChE possesses a larger volume in its
active site and can be a key factor in determining substrate
preference and inhibitor affinity [15].
The clinical antidepressants, fluoxetine, sertraline and
amitriptyline are used worldwide [16]. Besides their con-
firmed efficiency, there are many indirect and undesirable
effects presented in the therapy. Trycyclic antidepressants,
like amitriptilyne, are characterized by a high potential of
anticholinergic side effects including memory impairments,
delirium, behavioural toxicity and cardiovascular dysfunc-
tions [17]. Although these side effects are considered in the
literature, there is no conclusive data about the inhibition of
cholinesterases by amitriptyline nor by sertraline and fluox-
etine.
Recently, Barcellos et al. [18] reported that acetylcholi-
nesterase from cerebral cortex was inhibited by imipramine,
desipramine and amitriptyline at high concentrations. How-
ever, the activity of BuChE was not hitherto evaluated with
kinetic analysis in the presence of such compounds neither
in experimental animals nor in human serum. Furthermore,
to the best of our knowledge, the possible anti-cholinestera-
sic effect of selective serotonin reuptake inhibitors (SSRIs)
has not yet been studied in detail.
By the prerogatives outlined above, the purpose of the
present investigation was to evaluate whether different
antidepressants used in clinical practices induce changes
in the cholinestarase activities from human serum and
erythrocyte membrane.
2. Materials and methods
2.1. Materials
Acetylthiocholine iodide, DTNB (5,5V-dithiobis(2-nitro-
benzoic acid), fluoxetine and imipramine were purchased
from Sigma Chemical Co. (St. Louis, MO, USA). Sertraline
was obtained from Galena (Campinas, SP, Brazil). Mala-
thion (technical grade, 95%) was obtained from Indol do
Brasil SA (Curitiba, PR, Brazil) and further purified by
distillation under vacuum. All other reagents used in the
experiments were of analytical grade of the highest purity.
2.2. Humans
Human serum and erythrocyte ghost were obtained from
healthy volunteers (18–65 years old from both sexes) of the
University Hospital from Santa Maria, with written consent.
The protocol was approved by the Human Ethic Committee
of the University Hospital from Santa Maria. None of the
volunteers had a recurrent or a past history of psychiatric
illness, significant medical disorder, or drug, cigarette or
alcohol abuse. None of them had been taking any medi-
cation for at least the past 30 days.
From all participants, 10 ml of blood was collected in
vacutainer tubes, centrifuged at 3000 rpm for 10 min and the
serum was collected and used for the enzyme assays.
2.3. Erythrocyte membrane (ghost) preparations
From all participants, 20 ml of blood was collected into
heparinized tubes and the membrane was prepared essen-
tially as described by Niggli et al. [19].
2.4. Cholinesterase assay
Cholinesterase activities were determined by the method
of Ellman et al. [20], modified by Rocha et al. [21].
Hydrolysis rates v were measured at various acetylthiocho-
line (S) concentrations (0.008–0.8 mM) in 2 ml assay
solutions with 100 mM phosphate buffer, pH 7.5, and 1.0
mM DTNB at 25 jC. One hundred microliters of human
serum and 8–12 Ag from erythrocyte membrane were added
to the reaction mixture and preincubated for 3 min. The
hydrolysis was monitored by formation of the thiolate
dianion of DTNB at 412 nm for 2–3 min (intervals of 30
s) using a Hitachi 2001 spectrophotometer. All samples
were run in duplicate or triplicate. The antidepressants were
used in the range of 3–60 AM for fluoxetine, 0.3–12 AM for
sertraline and 3–60 AM for amitriptyline. Malathion was
diluted in 99% ethanol, to a final concentration of 0.95% in
the assay tubes (this final concentration of ethanol did not
affect the enzyme activity).
2.5. Protein determination
Protein was assayed by the method of Bradford [22]
using bovine serum albumin as standard.
2.6. Kinetic determinations
The kinetic of the interaction of antidepressants and
cholinesterase was determined using the Lineweaver–Burk
[23] double reciprocal plot, by plotting 1/v against 1/s
analysed over a range of acetylthiocholine concentrations
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(0.008–0.8 mM) in the absence and in the presence of
fluoxetine (3–60 Am), sertraline (0.3–12 AM) and amitrip-
tyline (3–60 AM). Km values were obtained by two different
estimates, 1/V vs. 1/S [23] and V vs. V/S [24–26]. The a and
Ki values were obtained using the associated plots of 1/Vand
Km/Vmax vs. [I]. The b value was obtained by the associated
plot of 1/(Km)o/(Vmax)o (Km)i/(Vmax)i and (1/Vo 1/Vi) vs.
1/[I]. IC50 was calculated according to the Dixon and Webb
[27] plot using 1/V vs. [I] with saturate substrate concen-
tration.
Fig. 1. Chemical structures of fluoxetine (a), sertraline (b) and amitripty-
line (c).
Fig. 2. Kinetic analysis of the inhibition of cholinesterase by fluoxetine (a),
sertraline (b) amitriptyline (c) in human serum. The graphs show double-
reciprocal plots of the cholinesterase experiments in the absence and in the
presence of the drugs. Hydrolysis rates v were measured at various substrate
(S) concentrations (0.008–0.8 mM) in 2 ml assay solutions with 100 mM
phosphate buffer (pH 7.5) and 1.0 mM DTNB (5,5V-dithiobis(2-nitro-
nenzoic acid) using 100 Al of serum and was preincubated for 3 min before
substrate addition. All experiments were repeated at least three times with
different sources of the enzyme and similar results were obtained. Data
presented were from three individual experiments. S.D. values were within
10% of the mean values.
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2.7. Statistical analysis
Data were analysed by one-way and two-way analysis of
variance followed by post hoc Duncan’s multiple range test
when appropriate. Differences between groups were con-
sidered significant when P < 0.05. All analyses were per-
formed using the Statistical Package for Social Sciences
(SPSS) software.
3. Results
At the micromolar range concentration, different classes
of antidepressants, including fluoxetine, sertraline and ami-
triptyline (Fig. 1) inhibited human serum cholinesterase
(Fig. 2). The order of inhibitory potency was sertraline>ami-
triptylineHfluoxetine. Analysis of kinetic data indicated
that the inhibition caused by all the antidepressants was
mixed in nature. Accordingly, while the Km values in-
creased, the Vmax decreased in a concentration-dependent
manner. The Km and Vmax for serum and erythrocyte ghost
AChE were calculated by the double reciprocal method of
Lineweaver and Burk [23] and by the method of Eadie and
Hofstee [24–26] (data not shown). The values of a and b
and Ki are depicted in Table 1.
The concentration of antidepressants required to inhibit
50% of cholinesterase activity was calculated using the
Dixon and Webb [27] plot at appropriate inhibitor concen-
trations. The IC50 values obtained for BuChE inhibition are
shown in Table 1.
In order to best characterize the site of interaction
between the antidepressant and serum cholinesterase, we
examined the influence of sertraline on the inhibitory effect
of malathion (Table 2). Malathion is not an inhibitor of
cholinesterase; however, commercial preparation of mala-
thion are usually contaminated with malaoxon, which is a
very potent cholinesterase inhibitor. In fact, malaoxon binds
covalently to a serine located at the bottom of the active site
gorge of the enzyme. Data from Table 2 clearly show that
malathion (malaoxon) inhibits the cholinesterase in a stable
way since the removal of inhibitor by gel filtration in a G-10
column did not restore (reaction B) the original activity. The
enzyme activity showed a slight recovery after filtration
when compared with enzyme activity that was not filtered in
the column. In contrast to malathion, the interaction of
sertraline with the cholinesterase is labile since the removal
of inhibitor by gel filtration led to complete recovery of the
enzyme activity (reaction C). The inhibition of the enzyme
caused by the sequential addition of sertraline followed 10
min later by addition of malathion was not different from
that observed in the presence of each of these compounds
alone (reaction D, no filtration). However, when the enzyme
was preincubated first with the antidepressant for 10 min
followed by preincubation for 10 min with malathion and
then gel filtration, an almost complete recovery of the
Table 1
a, b, Ki and IC50 values for cholinesterase from human serum
Fluoxetine Sertraline Amitriptyline
a 2.45 1.81 2.6
b 0 0.65 0.16
Ki (AM) 106 1.08 1.22
IC50 (AM) 32 4.05 9.43
The a, b, Ki and IC50 were calculated according Section 2. a is the factor by
which Km changes when the inhibitor occupies the enzyme. b is the factor
by which Vmax changes when the inhibitor occupies the enzyme. Values are
expressed as mean of three independent experiments performed in triplicate.
S.D. values were within 10% of the mean values.
Table 2
Effect of sertraline on malathion-induced cholinesterase inhibition
Preincubation Activity (Amol AcSCh/h/mg of protein)
First 10 min Last 10 min No filtration Filtration
(A) 5 Al of H2O 5 Al of ethanol 1.30F 0.19 1.28F 0.14
(B) 5 Al of malathion in ethanol 5 Al of H2O 0.77F 0.10 0.86F 0.11
(C) 5 Al of ethanol 5 Al of sertraline in H2O 0.77F 0.10 1.30F 0.21
(D) 5 Al of sertraline in H2O 5 Al of malathion in ethanol 0.73F 0.14 1.20F 0.11
(E) 5 Al of malathion in ethanol 5 Al of sertraline in H2O 0.51F 0.02 0.73F 0.10
The human serum (500 Al) was preincubated for 20 min as follows: (A) 10 min with 5 Al of water and sequentially followed by the addition of 5 Al of 99%
ethanol solution (to give a final concentration of 0.95% of ethanol) for more 10 min; (B) 10 min with 5 Al of malathion in 99% ethanol (to give a malathion
final concentration of 320 AM) and then 5 Al of water was added in the last 10 min; (C) 10 min with 5 Al of ethanol and then 5 Al of sertraline diluted in water
(to give a final concentration of 80 AM) in the last 10 min; (D) 5 Al of sertraline diluted in water (to give a final concentration of 80 AM) and after 10 min, the
addition of 5 Al of malathion diluted in ethanol (to give a final concentration of 320 AM); (E) During the first 10 min, serum was preincubated with 5 Al of
malathion diluted in ethanol (to give a final concentration of 320 AM) followed by the addition of 5 Al of sertraline (final concentration of 80 AM sertraline) in
the last 10 min. Following the second addition, the final concentration of the first drug added was diluted 1%. An aliquot of 100 Al of this preincubated mixture
was directly used to determine the enzymatic activity (no filtration), and an aliquot of 200 Al of the preincubated mixture was filtered through a Sephadex 10
(G-10) column. The column was eluted with 10 mM phosphate buffer (1 ml/min) at 25 jC. Finally, 200 Al of the fraction that contained the bulk of protein was
used to determine the enzyme activity. The dilution of protein caused by gel filtration varied from 1.8 to 2.3 times.
Statistical analysis (two-way ANOVA) with five groups (control, malathion, sertraline, sertraline plus malathion, and malathion plus sertraline) 2 gel filtration
(not filtered and gel filtered) yielded a significant main effect of inhibitors (malathion, sertraline and sertraline +malathion; P< 0.01) and a significant
inhibitors gel filtration interaction ( P < 0.01).
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enzyme activity was observed (reaction D, filtration). In
contrast with scheme D, when the serum was first incubated
with malathion for 10 min and then exposed to sertraline for
10 min, a stable inhibition of enzyme was observed even
after serum was gel-filtered (reaction E, filtration). In the
absence of gel filtration, the inhibitory effect caused by
preincubation with malathion followed by sertraline was
slightly higher than that observed in reaction D (where
serum was exposed to sertraline before malathion). In
summary, malathion, sertraline and sertraline +malathion
inhibited significantly the enzyme activity that was not gel
filtered; however, after gel filtration, only the enzyme
preincubated with malathion was inhibited. The preincuba-
tion with sertraline or sertraline followed by malathion and
gel filtration did not result in enzyme inhibition.
At the micromolar range concentration, sertraline and
amitriptyline inhibited human erythrocyte membrane
(ghost) (Fig. 3). The order of inhibitory potency was
sertraline>amitriptyline. Analysis of kinetic data indicated
that the inhibition caused by all the antidepressants was
mixed in nature. The Km and Vmax values obtained for
erythrocyte ghost were calculated by the double reciprocal
method of Lineweaver and Burk [23] and by the method of
Eadie and Hofstee [24–26] (data not shown). The values of
a and b and Ki are demonstrated in the Table 3.
4. Discussion
The antidepressants tested inhibited cholinesterase activ-
ities in an experimental approach using acetylthiocholine as
substrate. The inhibitory potency of these antidepressants
was different and varied depending on the enzyme source.
The differences could be due to chemical variation between
these compounds (Fig. 1), which results in distinct interac-
tions with the two classes of cholinesterases and to structural
differences between the enzymes tested (BuChE–serum or
AChE–erythrocyte membrane), mainly to primary and ter-
tiary enzyme structure peculiarities.
The dimensions and the microenvironment of the active
site gorge play a significant role in determining the selec-
tivity, affinity and hydrolysis rate of substrates and inhib-
itors of esterases [15,28]. In the case of cholinesterase, it
is plausible that these compounds bind at the bottom of the
active site gorge. Support to this can be obtained in the
study of Harel et al. [14], which demonstrated that the cry-
stal structure of tacrine (an inhibitor of AChE with a
structure similar to that of sertraline) in AChE binds at the
bottom of the active site gorge. The reversible binding of
antidepressants to the bottom of the active site gorge may
either decrease the velocity of S association to the catalytic
site (compatible with a reduction in the forward reaction
described below in step 2) or, if the drug remain associated
with the enzyme–product complex at the bottom of active
site gorge, the drug can cause a decrease in the rate of
Fig. 3. Kinetic analysis of the inhibition of cholinesterase sertraline (a) and
amitryptiline (b) in erythrocyte membranes (ghost). The graphs show
double-reciprocal plots of the cholinesterase experiments in the absence and
in the presence of the drugs. Hydrolysis rates v were measured at various
substrate (S) concentrations (0.008–0.8 mM) in 2 ml assay solutions with
100 mM phosphate buffer (pH 7.5) and 1.0 mM DTNB (5,5V-dithiobis(2-
nitronenzoic acid) with 8 to 12 Ag of protein. Enzyme preparation was
preincubated for 3 min before starting enzyme reaction by adding substrate.
All experiments were repeated at least three times and similar results were
obtained. Data presented were from three individual experiments. S.D.
values were within 10% of the mean values.
Table 3
a, b, Ki and IC50 values for cholinesterase from erythrocyte membranes
Sertraline Amitriptyline
a 1.55 3.17
b 0 0
Ki (AM) 64 143
IC50 (AM) 80 134
a, b, Ki and IC50 were calculated according to Section 2. Values are
expressed as the mean of three independent experiments performed in
triplicate. S.D. values were within 10% of the mean values.
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product dissociation from the catalytic site. In this case, the
complex ChE.Drug.S is converted to ChE.Drug.P and the
presence of the drug at the bottom of active site makes the
dissociation of product (compatible with a decrease in the
forward rate on step (5) described below) difficult.
The kinetic analysis of the effects of the antidepressants
on cholinesterase activity indicated a mixed inhibition for all
compounds because they increased the Km value and
decreased Vmax value. Further kinetic analysis revealed for
fluoxetine that the a>1 and b = 0; these values indicate a
mixed inhibition with a competitive partial system and a
noncompetitive pure system. Sertraline and amitriptyline
presented a>1 and b < 1, indicating a mixed inhibition with
a competitive and noncompetitive partial system. The values
for a>1 indicated essentially reversible inhibition.
We propose the following scheme for the interactions
between the compounds and cholinesterase:
ChEþ DrugZChE:Drug ð1Þ
ChE:Drugþ SZChE:Drug:S ð2Þ
ChE:Drug:SZChE:Sþ Drug ð3Þ
ChE:SZChE:P ð4Þ
ChE:PZChEþ P ð5Þ
Both binary (ChE.Drug or ChE.S) and ternary (ChE.
Drug.S) complexes could be formed. The complex ChE.
Drug.S liberates product at a lower rate, decreasing the
Vmax. The mixed inhibition type can represent an important
experimental characteristic from multisubstrate enzymes,
such as cholinesterase.
The results obtained with the column clearly indicated
that sertraline hinders the covalent binding of malathion to
the esteratic site of the enzyme and experimentally can
protect the enzyme from a stable inhibition by malathion. In
contrast to malathion, the interaction of sertraline with the
cholinesterase is labile since the removal of inhibitor by gel
filtration recovered completely the enzyme activity.
Although the enzymes studied in this work measured
peripheral cholinergic effects, it can be postulated that the
data obtained with erythrocyte membrane enzyme (AChE)
can predict some central action of these compounds. This
consideration is being postulated since the therapeutic
efficacy of the central AChE inhibitors of many compounds,
used in clinical routine, is sometimes related to their action
on the peripheral AChE from the erythrocyte source. On the
other hand, in a similar protocol, it is known that in rat
cerebral cortex, imipramine and amitriptyline only inhibit
AChE at the millimolar concentration [18]. Therefore,
subsequent approaches must be conducted to clarify these
data.
In conclusion, it was shown that antidepressants inhibited
acetylthiocholine hydrolysis in human serum and erythro-
cyte membrane by cholinesterases. The concentrations of
antidepressants necessary to inhibit serum cholinesterase are
relatively close to the clinical levels found after pharmaco-
logical use of sertraline and amitriptyline. Consequently,
undesirable pharmacological and toxicological side effects
of these antidepressants can be related, at least in part, to
inhibition of serum and erythrocyte cholinesterases.
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